S1PR1 signaling in the lymphatic vasculature regulates tertiary lymphoid organ formation

Active Project Grant Awarded Last action

Award ID
R01HL185377
Recipient
Awarding agency
Obligated
$676,865

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 9% complete
Place of performance
Oklahoma City, OK 73104, USA

Award details come from USAspending.gov.

About this award

The National Heart, Lung, and Blood Institute awarded the Oklahoma Medical Research Foundation $676,865 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate S1PR1 signaling in lymphatic vasculature and its role in tertiary lymphoid organ formation and inflammatory bowel disease pathology.

The research will test the hypothesis that S1PR1 deficiency in lymphatic endothelial cells promotes the formation of functionally protective tertiary lymphoid organs that mitigate intestinal inflammation. Work encompasses three specific aims: investigating the significance of tertiary lymphoid organs in inflammatory bowel disease pathology; determining the roles of microbiota and antigen-presenting cells in driving tertiary lymphoid organ development in S1PR1-deficient mice; and determining the lymphatic endothelial cell-specific mechanisms by which S1PR1 inhibits tertiary lymphoid organ development. The research employs mouse models and specialized laboratory techniques to explore previously unknown mechanisms of clinically relevant molecules. Findings may provide novel therapeutic opportunities for inflammatory bowel disease, which currently lacks curative pharmacological treatments and generates an estimated annual cost of $14.6 to $31.6 billion in the United States.

Performance will occur in Oklahoma City, Oklahoma, with work running from July 15, 2026, through March 31, 2030. The award is classified as a Project Grant, a standard assistance type for investigator-initiated research.

Description

Abstract
Impaired lymphatic vascular physiology can lead to vascular pathologies such as lymphedema, inflammation, and fibrosis. We have determined that the gpcr sphingosine-1 phosphate receptor 1 (S1PR1) is necessary to prevent excessive growth of lymphatic vessels. Furthermore, mice lacking S1PR1 in the lymphatic endothelial cells (LECS) developed immune cell rich tertiary lymphoid organs (TLOS) in the mesenteric tissue. TLOS develop in inflammatory bowel diseases such as crohn's disease and ulcerative colitis. However, the mechanisms of TLO development and their pathological significance are not fully understood. Building on our novel observations we will test our central hypothesis that S1PR1 deficiency in LECS promotes the formation of functionally protective TLOS that mitigate intestinal inflammation. We will test this hypothesis by achieving three specific aims: 1) investigate the significance of TLOS in IBD pathology. 2) determine the roles of microbiota and antigen-presenting cells in driving TLO development in S1PR1IΔLEC mice, and 3) determine the LEC-specific mechanisms by which S1PR1 inhibits TLO development. Inflammatory bowel disease is a severe disease of the GUT. Currently available pharmacological treatments are not curative, cause immunosuppression and increase the susceptibility to opportunistic infections. Thus, alternative treatments are urgently needed for this disease with an estimated annual cost of $14.6-31.6 billion in the US alone. Our work is significant because by understanding how lymphatic vasculature regulates TLO formation IT may provide novel opportunities to treat inflammatory bowel disease. Additionally, our work is innovative as IT will explore the previous unknown mechanisms of clinically relevant molecules using mouse models and challenging techniques.

Quick answers

Who received award R01HL185377?

R01HL185377 was awarded to Oklahoma Medical Research Foundation by National Heart Lung and Blood Institute (National Institutes of Health) on July 15, 2026.

How much is award R01HL185377 worth?

$676,865 has been obligated on R01HL185377.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award